TY - JOUR
AU - Shiwani, Hunain
AU - Artico, Jessica
AU - Moon, James C
AU - Gorecka, Miroslawa
AU - McCann, Gerry P
AU - Roditi, Giles
AU - Morrow, Andrew J.
AU - Mangion, Kenneth
AU - Lukaschuk, Elena
AU - Shanmuganathan, Mayooran
AU - Miller, Christopher A
AU - Chiribiri, Amedeo
AU - Alzahir, Mohammed
AU - Ramirez, Sara
AU - Lin, Andrew
AU - Swoboda, Peter P
AU - McDiarmid, Adam K
AU - Sykes, Robert
AU - Singh, Trisha
AU - Bucciarelli-Ducci, Chiara
AU - Dawson, Dana
AU - Fontana, Marianna
AU - Manisty, Charlotte
AU - Treibel, Thomas A
AU - Levelt, Eylem
AU - Arnold, Ranjit
AU - Young, Robin
AU - McConnachie, Alex
AU - Neubauer, Stefan
AU - Piechnik, Stefan K
AU - Davies, Rhodri H
AU - Ferreira, Vanessa M
AU - Dweck, Marc R.
AU - Berry, Colin
AU - OxAMI Study Investigators
AU - Greenwood, John P.
PY - 2024
DA - August
TI - Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19: A Prospective, Multicenter, Cohort Study
JO - JACC: Cardiovascular Imaging
EP - 1331
VL - 17
IS - 11
DO - https://doi.org/10.1016/j.jcmg.2024.06.008
AB - BackgroundHospitalized COVID-19 patients with troponin elevation have a higher prevalence of cardiac abnormalities than control individuals. However, the progression and impact of myocardial injury on COVID-19 survivors remain unclear.ObjectivesThis study sought to evaluate myocardial injury in COVID-19 survivors with troponin elevation with baseline and follow-up imaging and to assess medium-term outcomes.MethodsThis was a prospective, longitudinal cohort study in 25 United Kingdom centers (June 2020 to March 2021). Hospitalized COVID-19 patients with myocardial injury underwent cardiac magnetic resonance (CMR) scans within 28 days and 6 months postdischarge. Outcomes were tracked for 12 months, with quality of life surveys (EuroQol-5 Dimension and 36-Item Short Form surveys) taken at discharge and 6 months.ResultsOf 342 participants (median age: 61.3 years; 71.1% male) with baseline CMR, 338 had a 12-month follow-up, 235 had a 6-month CMR, and 215 has baseline and follow-up quality of life surveys. Of 338 participants, within 12 months, 1.2% died; 1.8% had new myocardial infarction, acute coronary syndrome, or coronary revascularization; 0.8% had new myopericarditis; and 3.3% had other cardiovascular events requiring hospitalization. At 6 months, there was a minor improvement in left ventricular ejection fraction (1.8% ± 1.0%;P &lt;0.001), stable right ventricular ejection fraction (0.4% ± 0.8%;P =0.50), no change in myocardial scar pattern or volume (P =0.26), and no imaging evidence of continued myocardial inflammation. All pericardial effusions (26 of 26) resolved, and most pneumonitis resolved (95 of 101). EuroQol-5 Dimension scores indicated an overall improvement in quality of life (P &lt;0.001).ConclusionsMyocardial injury in severe hospitalized COVID-19 survivors is nonprogressive. Medium-term outcomes show a low incidence of major adverse cardiovascular events and improved quality of life. (COVID-19 Effects on the Heart;ISRCTN58667920)
PB - JACC Journals
UR - https://hdl.handle.net/2164/24597
KW - Coronavirus (COVID-19)
KW - Hospital care
ER